

Express Mail No.: EV463104507US
Date of Deposit: September 29, 2005

Page 1 of 1
Attorney Docket No.: 26505-513 (RIB-007)

Please type a plus sign (+) in this box +

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/671,326
		Filing Date	September 25, 2003
		First Named Inventor	Wang
		Group Art Unit	1626
		Examiner Name	Nyeemah Grazier
		Attorney Docket Number	26505-513 (RIB-007)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
---------------	----------	--------------------------	------------	-------------------------------------	-------	-----------	----------------------------

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
---------------	----------	--------------------------------	----------------	-------------------------------------	-------	-----------	----------------------------

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B50	WO 02/081470 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10/17/02	
	B51	WO 03/035648 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	05/01/03	
	B52	WO 03/072575 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	09/04/03	
	B53	WO 2004/056817 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
	B54	WO 2004/056818 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
	B55	WO 2004/078770 A1	RIB-X PHARMACEUTICALS, INC.	09/16/04	
	B56	WO 2005/042554 A1	RIB-X PHARMACEUTICALS, INC.	05/12/05	
	B57	WO 2005/049632 A1	RIB-X PHARMACEUTICALS, INC.	06/02/05	
	B58	WO 2005/085266 A2	RIB-X PHARMACEUTICALS, INC.	09/15/05	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C18	Gregory et al. <i>J. Med. Chem.</i> , 32:1673-1681 (1989)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	11/07/05
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2075951v1

Express Mail No.:
Date of Deposit:

Page 1 of 2
Attorney Docket No.: 26505-513 (RIB-007)

Please type a plus sign (+) in this box

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1448/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/671,326
		Filing Date	September 25, 2003
		First Named Inventor	Wang
		Group Art Unit	1828
		Examiner Name	Nyemah Grazier
		Attorney Docket Number	26505-513 (RIB-007)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<i>MG</i>	A42	5,658,888	08-19-97	Koga et al.	514	29	10-19-94
<i>MG</i>	A44	6,878,691 B2	04-12-05	Or et al.	514	29	05-05-03

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<i>MG</i>	A43	2004/0157787 A1	08-12-04	Or et al.	514	28	11-19-03

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
<i>MG</i>	B59	WO 99/64416	ZENECA LIMITED GB	12-16-99	
<i>MG</i>	B60	WO 99/64417	ZENECA LIMITED GB	12-16-99	
<i>MG</i>	B61	WO 00/40589	PLJVA, FARMACEUTSKA INDUSTIJA. DIONICKO DRUSTVO	07-13-00	
<i>MG</i>	B62	WO 01/40238 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	08-07-01	
<i>MG</i>	B63	WO 02/051855 A2	KOSAN BIOSCIENCES, INC	07-04-02	
<i>MG</i>	B64	WO 02/080841 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02	
<i>MG</i>	B65	WO 02/081468 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02	
<i>MG</i>	B66	WO 02/081469 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02	
<i>MG</i>	B67	WO 02/096890 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-05-02	
<i>MG</i>	B68	WO 02/096918 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-05-02	
<i>MG</i>	B69	WO 2004/013153 A2	ZAMBON GROUP S.P.A.	12-12-04	



12/1/05

Express Mail No.:
Date of Deposit:Page 2 of 2
Attorney Docket No.: 26505-513 (RIB-007)

<i>MS</i>	B70	WO	2004/048392 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	08-10-04		
<i>MS</i>	B71	WO	2004/058819 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07-08-04		
<i>MS</i>	B72	EP	0643058 B1	CHUGAI SEIYAKU KABUSHIKI KAISHA TOKYO 115 JP	08-19-98		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
<i>MS</i>	C19	Jones, P.H., and Powley, E.K., "Chemical Modifications of Erythromycin Antibiotics. I. 3'-De(dimethylamino)erythromycin A and B," J. Org. Chem., 33:665-670 (1968).
<i>MS</i>	C20	Stenmark, Heather G., et al., "Biomimetic Synthesis of Macrolide/Ketolide Metabolites through a Selective N-Demethylation Reaction," J. Org. Chem., 65:3875-3878 (2000).
<i>MS</i>	C21	Liang, Chang-Heing, et al., "Synthesis and Biological Activity of New 5'-O-Sugar Modifies Ketolide and 2-Fluoro-Ketolide Antibiotics," Bioorganic & Medicinal Chem. Letters, 15:1307-1310 (2005).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>MS</i>	Date Considered	12/01/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.